APRE vs DHR · $10.4M cap vs P/E 39, rev $24.57B
Aprea Therapeutics Inc (APRE) versus Danaher Corporation (DHR) — a side-by-side from cached financials, not a winner call.
Aprea Therapeutics Inc (APRE) is a biotechnology company listed on US.
Danaher Corporation (DHR) is a diagnostics & research company listed on US.
APRE does not have a complete income-statement cache yet.
Latest reported DHR revenue for 2025-12-31 was $24.57B. Net income was $3.61B. Revenue was up 2.9% from 2024-12-31 to 2025-12-31. DHR currently screens at market cap $144.18B and trailing P/E 39.0.
APRE currently screens at market cap $10.4M. DHR currently screens at market cap $144.18B and trailing P/E 39.0.
Not investment advice. Open the APRE and DHR stock pages for the full models.
Not investment advice.